Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:focusesOn |
gptkb:respiratory_syncytial_virus_(RSV)
antiviral therapies |
| gptkbp:foundedIn |
2011
|
| gptkbp:founder |
Ken Powell
Stuart Cockerill |
| gptkbp:headquartersLocation |
gptkb:London,_United_Kingdom
|
| gptkbp:leadProduct |
RV521
sisunatovir |
| gptkbp:website |
https://www.reviral.co.uk/
|
| gptkbp:bfsParent |
gptkb:Novo_Holdings
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
ReViral
|